Most Women in Menopause Never Get Treated. Here Is the Data.

A few weeks ago I was sitting across from a woman I admire. Sharp, accomplished, running more than most people half her age. She told me, almost in passing, that she had not slept through the night in two years and assumed that was just the deal now. She had never raised it with a doctor. Not once. I have heard a version of that sentence so many times inside our community that I went looking for the data, and the data is worse than the anecdotes.

Here is the headline finding. In 2021, only about 2.1 million American women ages 45 to 64 were treated for menopause, according to an analysis by the AARP Public Policy Institute using federal Medical Expenditure Panel Survey data. That works out to roughly 5 percent of women in that age group, and only about 20 to 25 percent of women actually experiencing menopause symptoms. Put plainly, four out of five women who could be helped are getting nothing.

You are not the only one, and that matters

Menopause is not a disease. It is a transition, the end of the menstrual cycle, and for a long stretch of life that follows. But the symptoms are real and treatable, which is exactly why so much silence around them costs so much. Beth Carter, who wrote the AARP brief, frames menopause as a health condition precisely because its discomforts can be eased with the right care.

The scale is easy to underestimate. Roughly 2 million women in the U.S. reach menopause every year, and 8 to 10 million are living with symptoms at any given time. Against that, 2.1 million treated looks almost respectable until you remember it is counting all women 45 to 64, most of whom are not symptomatic in a given year. Among the women who are, only one in four or five is getting treated.

The gap is not the same for every woman

This is the part I want every MamaBee member to sit with, because the silence is not evenly distributed. The AARP analysis found that Hispanic women (2.7 percent) and non-Hispanic Black women (2.5 percent) were less than half as likely as non-Hispanic white women (6.3 percent) to be treated for menopause. Treatment also rose sharply with family income, with education, and with the kind of insurance a woman carried.

Insurance tells the same story from a different angle. Women with employer-sponsored coverage were treated at 5.8 percent, more than double the 2.6 percent rate among uninsured women. College and beyond pushed treatment up to 7.2 percent, against 3.2 percent for women with a high school education or less.

The brief is careful not to claim it can pin down the cause of these gaps, and I will be too. What the broader research adds is uncomfortable. The long-running Study of Women's Health Across the Nation found that Black women had the highest prevalence and the longest duration of menopausal symptoms, and were the least likely to be treated. The women carrying the heaviest symptom load are the ones least likely to get help. That is not a footnote. That is the story.

The women carrying the heaviest symptom load are the ones least likely to get help.

Why so many women went without

Three things stacked up. There is genuine stigma and confusion around menopause, the kind that makes a brilliant woman decide her insomnia is just the deal now. There is a training gap, an expert panel convened by the U.S. Department of Health and Human Services concluded years ago that clinical education on women's health is inadequate, and many providers simply were never taught to manage menopause. And then there is the single biggest reason, which deserves to be told accurately because it has been told sloppily for twenty years.

In 2002, the Women's Health Initiative reported that a specific combined estrogen-plus-progestin therapy raised the risk of heart disease, stroke, blood clots, and breast cancer. Prescriptions collapsed almost overnight. Doctors stopped offering hormone therapy, and a generation of women absorbed the message that it was dangerous.

Here is the correction, and it is the part the headlines usually skip. The WHI was a real, rigorous trial, and its core conclusion still stands. Hormone therapy should not be used to prevent chronic disease, full stop. But the WHI was never designed to test hormone therapy for treating menopause symptoms, and most of its participants were well past the menopause transition, in their 60s and 70s. A 2024 review in JAMA, summarized by the NIH, makes the timing point directly. For women under 60 and within ten years of menopause onset, with low-to-average cardiovascular and breast cancer risk, the benefits of treating symptoms can outweigh the risks. The fear that spread in 2002 was applied to a much broader group of women than the evidence ever justified.

What changed in 2025

If you read the AARP brief on its own, you would think the story ends with confusion that persists. It does not anymore. On November 10, 2025, the FDA announced it would remove the black box warnings about cardiovascular disease, breast cancer, and probable dementia from estrogen-containing hormone therapy products, calling more than two decades of those warnings overstated. The agency asked manufacturers to rewrite labels with age-specific guidance, noting that benefits for most women generally outweigh risks when therapy starts within ten years of menopause onset.

I want to be precise here, because precision is the whole point. This was not a blanket all-clear. As Harvard Health reported, the boxed warning for endometrial cancer on systemic estrogen-alone products stays in place, and the changes are about giving women accurate information rather than declaring the therapy risk-free. The shift in language matters too. Clinicians increasingly say "hormone therapy" rather than "hormone replacement therapy," since it replaces only a fraction of what the ovaries once produced.

What treatment actually looks like

Hormone therapy is the most studied option, and The Menopause Society, formerly the North American Menopause Society, calls it the most effective treatment for hot flashes, night sweats, and the genitourinary symptoms of menopause. In the AARP data, about two-thirds of treated women, roughly 1.4 million, received a hormone therapy prescription. SSRIs, a non-hormonal option, were second at about 17 percent.

It is not for everyone, and I will not pretend otherwise. Women with certain conditions, including some estrogen-dependent cancers, blood clots, and liver disease, are generally advised against hormone therapy, and non-hormonal medications exist precisely for them. There is also a quietly frustrating pattern in the data. Treatment works best when started early, yet the AARP analysis found hormone therapy was far more common in older women in late menopause (76 percent of women 57 to 64) than in younger women in the transition (56 percent of women 45 to 56). The window when it helps most is the window women are least likely to use it.

The cost of doing nothing is not zero

It is tempting to file untreated menopause under "uncomfortable but harmless." The data pushes back. Women who were treated for menopause carried noticeably higher rates of certain comorbid conditions than women who were not, including thyroid disorders (25 percent versus 13 percent), sleep disorders (19 versus 8), depression (21 versus 11), and anxiety (20 versus 12). The brief is honest that this is association, not proven cause, and treated women may simply be in closer contact with the health system. But it points at something we already feel in our community. The symptoms tangle with sleep, mood, and energy, and leaving them unaddressed is its own kind of slow tax on a woman's midlife.

What to do with all of this

I am not a clinician, and nothing here is medical advice. What I can offer is the thing that was missing for the woman across that table from me, which is permission to treat this as a real medical question worth raising. If the symptoms are interfering with your life, that is reason enough to bring them to someone trained to help.

If your current provider waves it off, that is information, not a verdict. The Menopause Society keeps a directory of menopause-trained practitioners you can search by location. Finding someone who actually specializes in this is often the difference between two years of bad sleep and a real conversation.

We talk a lot at MamaBee about visibility, about women being seen and recognized. This is the quietest version of that. Half a generation of women decided their own discomfort was not worth a doctor's attention. The science just changed in their favor. The least we can do is make sure the women in our circles know it.

This article is for general information and is not medical advice. It does not establish a clinician-patient relationship. Menopause care decisions, including whether to use hormone therapy, should be made with a qualified healthcare provider who knows your history. If you are experiencing symptoms that affect your daily life, please speak with a clinician.